We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
+3.08%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$3.55B
AUM Growth
-$61.4M
Cap. Flow
+$136M
Cap. Flow %
3.83%
Top 10 Hldgs %
70.18%
Holding
30
New
3
Increased
10
Reduced
6
Closed
–

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$27.1M
2
VYGR icon
Voyager Therapeutics
VYGR
+$26.4M
3
WVE icon
Wave Life Sciences
WVE
+$25M
4
AKCA
Akcea Therapeutics Inc
AKCA
+$24.5M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$15M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$7.54M
2
JUNO
Juno Therapeutics, Inc.
JUNO
+$6.48M
3
SAGE
Sage Therapeutics
SAGE
+$4.85M
4
HALO icon
Halozyme
HALO
+$1.95M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$1.89M

Sector Composition

Rank Sector Weight
1 Healthcare 92.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
1
Ionis Pharmaceuticals
IONS
$9.4B
$409M 11.52%
8,136,334
+274,400
+3% +$15M
CELG
2
DELISTED
Celgene Corp
CELG
$357M 10.06%
3,424,298
+240,000
+8% +$27.1M
INCY icon
3
Incyte
INCY
$24.4B
$350M 9.86%
3,698,322
+30,000
+0.8% +$3.14M
NBIX icon
4
Neurocrine Biosciences
NBIX
$16.6B
$268M 7.54%
3,452,753
-10,000
-0.3% -$682K
VRTX icon
5
Vertex Pharmaceuticals
VRTX
$126B
$221M 6.23%
1,475,445
– –
GILD icon
6
Gilead Sciences
GILD
$165B
$199M 5.6%
2,774,596
– –
RDUS
7
DELISTED
Radius Health, Inc.
RDUS
$181M 5.1%
5,698,799
+200,000
+4% +$6.28M
HALO icon
8
Halozyme
HALO
$12.2B
$173M 4.86%
8,520,137
-105,914
-1% -$1.95M
SAGE
9
DELISTED
Sage Therapeutics
SAGE
$172M 4.84%
1,042,439
-50,000
-5% -$4.85M
ALXN
10
DELISTED
Alexion Pharmaceuticals
ALXN
$162M 4.56%
1,354,428
– –
ESPR
11
DELISTED
Esperion Therapeutics
ESPR
$156M 4.38%
2,362,964
+265,000
+13% +$14.3M
AGIO icon
12
Agios Pharmaceuticals
AGIO
$1.93B
$156M 4.38%
2,719,998
-30,000
-1% -$1.89M
ALNY icon
13
Alnylam Pharmaceuticals
ALNY
$29.3B
$134M 3.76%
1,051,338
-60,000
-5% -$7.54M
JUNO
14
DELISTED
Juno Therapeutics, Inc.
JUNO
$88M 2.48%
1,925,000
-130,000
-6% -$6.48M
TSRO
15
DELISTED
TESARO, Inc.
TSRO
$86.7M 2.44%
1,046,193
+50,000
+5% +$4.9M
REGN icon
16
Regeneron Pharmaceuticals
REGN
$80.8B
$77.1M 2.17%
205,000
– –
MGNX icon
17
MacroGenics
MGNX
$257M
$49.4M 1.39%
2,600,412
+200,000
+8% +$3.73M
AVXS
18
DELISTED
AveXis, Inc. Common Stock
AVXS
$44.6M 1.26%
402,800
– –
MYOV
19
DELISTED
Myovant Sciences Ltd.
MYOV
$44.3M 1.25%
3,507,882
+30,000
+0.9% +$402K
ITCI
20
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$31.9M 0.9%
2,200,000
– –
WVE icon
21
Wave Life Sciences
WVE
$1.2B
$30M 0.85%
+856,096
New +$25M
ICPT
22
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$28.4M 0.8%
485,719
– –
ALDR
23
DELISTED
Alder Biopharmaceuticals
ALDR
$25.9M 0.73%
2,266,008
– –
VYGR icon
24
Voyager Therapeutics
VYGR
$201M
$25.6M 0.72%
+1,539,520
New +$26.4M
AKCA
25
DELISTED
Akcea Therapeutics Inc
AKCA
$21.7M 0.61%
+1,248,650
New +$24.5M
1
2

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 10.02% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 17.19% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q4 2017 Portfolio in Review

As of Q4 2017, BB Biotech held 30 positions worth $3.55B, down 1.7% from $3.61B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

BB Biotech deployed $136M of net new capital in Q4 2017, opening 3 new positions and adding to 10 existing holdings. Its largest new stake was Voyager Therapeutics: 1,539,520 shares worth $25.6M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 92% a quarter earlier.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $7.54M trimmed.

  • BB Biotech's largest Q4 2017 buy was Voyager Therapeutics: 1,539,520 shares worth $25.6M.
  • BB Biotech added most to Celgene Corp in Q4 2017, an estimated $27.1M increase.
  • BB Biotech's biggest Q4 2017 reduction was Alnylam Pharmaceuticals, cutting an estimated $7.54M.
  • BB Biotech's ten largest holdings make up 70% of its $3.55B portfolio in Q4 2017.
  • BB Biotech opened 3 new positions and closed 0 in Q4 2017.
  • BB Biotech's portfolio value fell 1.7% quarter-over-quarter to $3.55B.

Based on BB Biotech's 13F filing for Q4 2017, filed 14 Feb 2018.